Advanced

Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.

Cisbani, G; Drouin-Ouellet, Janelle LU ; Gibrat, C; Saint-Pierre, M; Lagacé, M; Badrinarayanan, S; Lavallée-Bourget, M H; Charest, J; Chabrat, A and Boivin, L, et al. (2015) In Neurobiology of Disease 82. p.430-444
Abstract
The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3weeks post-surgery. Importantly, we report that cystamine has neurorestorative properties 5weeks post-lesion as seen on the number of nigral dopaminergic neurons which is comparable with treatments of cysteamine, the reduced form of cystamine used in the clinic, as well as rasagiline,... (More)
The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3weeks post-surgery. Importantly, we report that cystamine has neurorestorative properties 5weeks post-lesion as seen on the number of nigral dopaminergic neurons which is comparable with treatments of cysteamine, the reduced form of cystamine used in the clinic, as well as rasagiline, increasingly prescribed in early parkinsonism. All three compounds induced neurite arborization of the remaining dopaminergic cells which was further confirmed in ex vivo dopaminergic explants derived from Pitx3-GFP mice. The disease-modifying effects displayed by cystamine/cysteamine would encourage clinical testing. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Neurobiology of Disease
volume
82
pages
430 - 444
publisher
Elsevier
external identifiers
  • pmid:26232588
  • wos:000364980000041
  • scopus:84939627579
ISSN
0969-9961
DOI
10.1016/j.nbd.2015.07.012
language
English
LU publication?
yes
id
4a66a39f-93ee-4156-9e5f-f6625eca888a (old id 7845059)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26232588?dopt=Abstract
date added to LUP
2015-09-05 11:52:24
date last changed
2017-08-27 03:32:07
@article{4a66a39f-93ee-4156-9e5f-f6625eca888a,
  abstract     = {The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3weeks post-surgery. Importantly, we report that cystamine has neurorestorative properties 5weeks post-lesion as seen on the number of nigral dopaminergic neurons which is comparable with treatments of cysteamine, the reduced form of cystamine used in the clinic, as well as rasagiline, increasingly prescribed in early parkinsonism. All three compounds induced neurite arborization of the remaining dopaminergic cells which was further confirmed in ex vivo dopaminergic explants derived from Pitx3-GFP mice. The disease-modifying effects displayed by cystamine/cysteamine would encourage clinical testing.},
  author       = {Cisbani, G and Drouin-Ouellet, Janelle and Gibrat, C and Saint-Pierre, M and Lagacé, M and Badrinarayanan, S and Lavallée-Bourget, M H and Charest, J and Chabrat, A and Boivin, L and Lebel, M and Bousquet, M and Lévesque, M and Cicchetti, F},
  issn         = {0969-9961},
  language     = {eng},
  pages        = {430--444},
  publisher    = {Elsevier},
  series       = {Neurobiology of Disease},
  title        = {Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.},
  url          = {http://dx.doi.org/10.1016/j.nbd.2015.07.012},
  volume       = {82},
  year         = {2015},
}